DRKS00029051招募中不适用
Prospective observational study molecular tumor board of the Comprehensive Cancer Center Mainfranken of the University Hospital of Würzburg - MTB-WÜ
niversitätsklinikum Würzburg0 个研究点目标入组 998 人开始时间: 2022年5月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 998
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Recommendation in the organ tumor board for a discussion in the molecular tumor board
- •- Guideline-based and evidence-based therapy already exhausted or to be exhausted in the foreseeable future
- •- Molecular genetic findings with unclear relevance
- •- Results of routine diagnostics not sufficiently informative
排除标准
- •- Lack of ability to give consent or informed consent for registry study.
- •- Lack of consent for tissue and data release and lack of consent for genetic testing/panel diagnostics.
研究者
相似试验
已完成
不适用
Prospective observational study of cancer-associated thrombosis in patients with newly diagnosed pancreatic cancerpancreatic cancerJPRN-UMIN000044564Japanese Red Cross Okayama Hospital54
招募中
Unknown
Prospective observational study of cancer-associated thrombosis in patients with newly diagnosed biliary tract cancerbiliary tract cancerJPRN-UMIN000048891Japanese Red Cross Okayama Hospital30
进行中（未招募）
不适用
A clinical registry for longitudinal data on the clinical, psychosocial, and economic impact of lung cancer treatment in ItalyCancerISRCTN67197140niversity of L'Aquila1,000
进行中（未招募）
不适用
Pathological response of chemotherapy in oral cancersCTRI/2016/02/006609A60
招募中
不适用
Register study of the Molecular Tumor Board (tumor entity-spanning molecular characterization program to evaluate individualized tumor biology-guided therapy in adults with rare and advanced tumor entities)Cross-tumor entity (adult patients = 18 years of age with any advanced tumor disease or with rare tumor entity (incidence of less than one case per 100,000 population)).N/ADRKS00025847niversitätsklinikum Freiburg Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation1,000